NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Ethicon

Status

Terminated

Conditions

Non-Small-Cell Lung Carcinoma

Carcinoma, Non-Small Cell Lung

Cancer of the Lung

Cancer of Lung

Neoplasms, Lung

Lung Cancer

Non-Small Cell Lung Cancer

Treatments

Device: Microwave Ablation

Study type

Interventional

Funder types

Industry

Identifiers

NCT03603652

NEU_2017_06

Details and patient eligibility

About

Patients with medically inoperable primary soft tissue lesion of the lung will have transbronchial microwave ablation performed via transbronchial approach by an interventional pulmonologist or thoracic surgeon using CT imaging. Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging. Patients will be followed for one year following the ablation procedure for efficacy and safety.

Full description

Patients with medically inoperable primary soft tissue lesion of the lung (lesions less than or equal to 2cm and located in the outer two-thirds of the lung and not closer than 1cm to the pleura) will have transbronchial microwave ablation performed using CT imaging. All ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.

Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging.

Patients will be followed for one year following the ablation procedure for efficacy and safety with specific follow-up visits at 30 days, 6 months, and 12 months post-ablation. A user experience questionnaire is completed by the treating physician to better understand the ease of the procedure.

Enrollment

10 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed informed consent.
Patients ≥ 18 years old.
Performance status 0-2 via ECOG (Eastern Cooperative Oncology Group) classification.
Willing to fulfill all follow-up visit requirements.
Medically inoperable primary soft tissue lesion of the lung or patient election not to have surgery. (Medically inoperable is defined per the following indicators: post op predictive FEV1 (forced expiratory volume in 1 second) < 40%; DLCO (diffusing capacity of the lung for carbon monoxide) < 40%; hypoxemia or hypercapnia diabetes with end-organ damage; or severe cerebral, cardiovascular, peripheral vascular disease, or chronic heart disease)
One soft tissue lesion ≤ 2 cm in the outer two thirds of the lung and not closer than 1 cm to the pleura.

(Outer two thirds of the lung is defined as peripheral beyond the segmental airway, past the segmental bronchi, such that proximal endobronchial soft tissue lesions are avoided; soft tissue lesions should not be contiguous with the pleura)
Radiographic resolution of pneumonia

Exclusion criteria

Scheduled concurrent procedure for the target soft tissue lesion other than those that are lung related.
Pregnant or breastfeeding.
Physical or psychological condition that would impair study participation.
Patients with uncorrectable coagulography at time of screening.
Patient with implantable devices, including pacemakers or other electronic implants.
Prior pneumonectomy or bronchiectasis.
Severe neuromuscular disease.
Platelet count ≤ 50,000/mm3.
ASA (American Society of Anesthesiologists) score of ≥ 4.
Inability to tolerate anesthesia.
Expected survival less than 6 months.
Clinically significant hypertension.
Chronic ventilator support, which uses bi-level positive airway pressure (PAP).
Endobronchial soft tissue lesions proximal to the segmental airways